Jeffrey Lu, Engine Biosciences CEO

En­gine Bio­sciences bags $27M Se­ries A ex­ten­sion to ad­vance pre­ci­sion med­i­cine plat­form in on­col­o­gy

En­gine Bio­sciences has raised $27 mil­lion in a Se­ries A ex­ten­sion with an eye to ad­vance its dis­cov­ery-stage pre­ci­sion on­col­o­gy pro­grams, which lever­age both ma­chine learn­ing and CRISPR screen­ing tech­nol­o­gy.

The ex­ten­sion raise was led by Po­laris Part­ners with sup­port from ex­ist­ing in­vestors Clavyst­Bio, In­vus and ED­BI, as well as new back­ers Coro­net Ven­tures and SEEDS Cap­i­tal. It brings the to­tal funds raised by the trans-Pa­cif­ic biotech since in­cep­tion to $86 mil­lion, in­clud­ing $70 mil­lion in to­tal Se­ries A pro­ceeds.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.